First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis

Nerich, Virginie; Chelly, J.; Montcuquet, P.; Chaigneau, L.; Villanueva, Cristian; Fiteni, Frédéric; Meneveau, Nathalie; Perrin, Sophie; Voidey, A.; Monnot, Tess; Pivot, Xavier; Limat, Samuel

doi:10.1177/1078155213508440

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, considering triple-negative breast cancer in France, bevacizumab costs EUR 13,330,631 per year, hence the decision of most other countries to reverse the approval of bevacizumab in breast cancer, as there was no improvement in OS in addition to significant costs. Besides, the drug is considered not to be cost-effective, based on its cost per year of life extended [14]. The RIBBON-2 trial which involved 684 women with HER2-negative metastatic breast cancer who had already received one course of chemotherapy has demonstrated that adding bevacizumab to chemotherapy as a second-line treatment increased PFS by around 2 months; in this study, some patients taking bevacizumab also experienced longer time to disease progression, as 2 months remains an average [15].…”

Section: Resultsmentioning

confidence: 99%

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study

et al. 2019

View full text Add to dashboard Cite

Background: Triple-negative breast cancer remains a disease with poor prognosis and few treatment options, due to the lack of therapeutic targets. Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer. Despite the fact that the benefit was particularly significant for triple-negative breast cancer with its approval in 2008 by the FDA, this decision was later reversed as there was no improvement in overall survival in addition to significant costs. Objectives: The scope of the present study is to focus on the role of bevacizumab in triple-negative breast cancer through the analysis of overall survival, progression-free survival, and cost benefit among 45 patients in a French monocentric study and to discuss new paradigms of endpoints. Methods: All patients diagnosed with metastatic triple-negative breast cancer, for whom first-line treatment was bevacizumab in combination with paclitaxel between January 2011 and April 2018 were included in this single-center retrospective study, and a chart review of all recruited subjects was performed from medical records. Results: In this real-life study among 45 patients with metastatic triple-negative breast cancer, bevacizumab provided a significant benefit for a category of patients, with longer median progression-free survival and the ability of maintenance therapy associated to limited side effects. Conclusions: Beyond being the phoenix of breast oncology and a magnet of controversy, the case of bevacizumab in metastatic breast cancer highlights one of the greatest challenges in oncology, namely to balance modest clinical benefits with exponential costs. A balance needs to be found between health care affordability, high price of progress, and the best medical decision for the patients, in order to avoid the “unbreathable tipping point” we are actually dealing with.

show abstract

Section: Resultsmentioning

confidence: 99%

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Taxanes can be used as single agent or in combination with other treatments such as the combination of anthracycline with taxanes that improve the quality of life better than anthracycline or taxanes treatment alone [ 5 , 133 ]. In addition, combination of taxanes plus biological drugs such as trastuzumab showed improvement in overall survival in patients with MBC [ 134 ]. Furthermore, combination of lapatinib with docetaxel and trastuzumab can be used as a first-line treatment of HER2-positive MBC [ 135 ].…”

Section: Treatments Of Metastatic Breast Cancermentioning

confidence: 99%

Metastatic and triple-negative breast cancer: challenges and treatment options

Al-Mahmood

Sapiezynski

Garbuzenko

et al. 2018

Drug Deliv. and Transl. Res.

411

258

View full text Add to dashboard Cite

The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.

show abstract

“…It is a sound deduction that a treatment aimed at reducing the blood supply of a tumor would also reduce the delivery of any other therapy, such as chemotherapy, which is also important for radiotherapy for anti-angiogenesis agents and may reduce the oxygen supply necessary for a response to radiotherapy ( 16 ). However, synergism of anti-angiogenetics and chemotherapeutics has been observed in patients with colon cancers ( 105 ), non-small cell lung cancers ( 106 ), and breast cancers ( 107 , 108 ). One explanation is that with the blockage of VEGF signaling, anti-angiogenetics induces a normalization of newly formed vessels, and thus, reduces the interstitial tissue pressure (ITP) within tumors, allowing enhanced delivery of chemotherapy to the tumors ( 7 ).…”

Section: Strategy For Advanced Osteosarcoma In the Era Of Targeted Thmentioning

confidence: 99%

Anti-angiogenesis target therapy for advanced osteosarcoma

Xie

Guo

2017

Oncology Reports

View full text Add to dashboard Cite

Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited treatment options. The greatest advancement in treatments occurred in the 1980s when multi-agent chemotherapy, including doxorubicin, cisplatin, high-dose methotrexate, and, in some regimens, ifosfamide, was demonstrated to improve overall survival compared with surgery alone. However, standard chemotherapeutic options have been limited by poor response rates in patients with relapsed or advanced cases. It has been reported that VEGFR expression correlates with the outcome of patients with osteosarcoma and circulating VEGF level has been associated with the development of lung metastasis. At present, it seems to us that progress has not been made since Grignani reported a phase II cohort trial of sorafenib and sorafenib combined with everolimus for advanced osteosarcoma, which, in a sense, have become a milestone as a second-line therapy for osteosarcoma. Although the recognization of muramyltripepetide phosphatidyl-ethanolamine has made some progress based on its combination with standard chemotherapy, its effect on refractory cases is controversial. Personalized comprehensive molecular profiling of high-risk osteosarcoma up to now has not changed the therapeutic prospect of advanced osteosarcoma significantly. Thus, how far have we moved forward and what therapeutic strategy should we prefer for anti-angiogenesis therapy? This review provides an overview of the most updated anti-angiogenesis therapy in OS and discusses some clinical options in order to maintain or even improve progression-free survival.

show abstract

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis

Cited by 3 publications

References 25 publications

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study

Metastatic and triple-negative breast cancer: challenges and treatment options

Anti-angiogenesis target therapy for advanced osteosarcoma

Contact Info

Product

Resources

About